Insulet (PODD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual meeting scheduled for May 20, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by May 19, 2026.
Voting matters and shareholder proposals
Election of three directors: Luciana Borio, Michael R. Minogue, and Timothy C. Stonesifer, with board recommending a vote in favor.
Advisory vote to approve executive compensation, with board recommending approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026, recommended by the board.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Three director nominees are presented for election at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Insulet
- 31% revenue growth in 2025 and double-digit growth guidance for 2026, driven by global expansion.PODD
Q4 202511 Apr 2026 - Record growth, innovation, and strong governance drive shareholder proposals and executive pay.PODD
Proxy filing6 Apr 2026 - Achieved $2.7B revenue in 2025, leading AID market growth and advancing global diabetes care.PODD
Investor presentation18 Feb 2026 - Innovation, market leadership, and global expansion drive strong growth through 2028.PODD
44th Annual J.P. Morgan Healthcare Conference3 Feb 2026 - Targets 29–30% revenue growth in 2025 and over 1M users by 2028 with major product launches.PODD
Investor Day 20253 Feb 2026 - SECURE-T2D delivered robust results, paving the way for broader adoption and future innovation.PODD
Baird's ADA 2024 Webcast Takeaways3 Feb 2026 - Q2 revenue up 23%, net income boosted by tax benefit, guidance raised on Omnipod 5 growth.PODD
Q2 20242 Feb 2026 - Omnipod 5's innovation and CGM integration fuel strong growth and expanded guidance.PODD
Jefferies Global Healthcare Conference1 Feb 2026 - Early Type 2 approval and global expansion set the stage for strong growth and margin gains.PODD
2024 Wells Fargo Healthcare Conference22 Jan 2026